Spots Global Cancer Trial Database for prexasertib
Every month we try and update this database with for prexasertib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer | NCT02555644 | Head and Neck N... | Prexasertib Cisplatin Cetuximab Intensity Modul... | 18 Years - | Eli Lilly and Company | |
| A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer | NCT02778126 | Advanced Cancer | [¹⁴C]Prexaserti... Prexasertib | 18 Years - | Eli Lilly and Company | |
| A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors | NCT03495323 | Cancer | LY3300054 Prexasertib | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer | NCT03414047 | Ovarian Cancer | Prexasertib | 18 Years - | Eli Lilly and Company | |
| A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer | NCT02555644 | Head and Neck N... | Prexasertib Cisplatin Cetuximab Intensity Modul... | 18 Years - | Eli Lilly and Company | |
| A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers | NCT02514603 | Neoplasm | Prexasertib | 20 Years - | Eli Lilly and Company | |
| A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer | NCT02860780 | Advanced Cancer Metastatic Canc... Colorectal Canc... Non-small Cell ... | prexasertib ralimetinib | 18 Years - | Eli Lilly and Company | |
| Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial | NCT03735446 | Acute Myeloid L... Myelodysplastic... | Prexasertib Mitoxantrone Etoposide Cytarabine | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer | NCT02124148 | Neoplasm Metast... Colorectal Neop... Breast Cancer | Prexasertib Cisplatin Cetuximab G-CSF Pemetrexed Fluorouracil LY3023414 Leucovorin | 18 Years - | Eli Lilly and Company | |
| A Phase 1 Study in Participants With Advanced Cancer | NCT01115790 | Advanced Cancer Squamous Cell C... Carcinoma, Squa... Lung Squamous C... Anal Squamous C... Carcinoma, Non-... | Prexasertib | 18 Years - | Eli Lilly and Company | |
| A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer | NCT02735980 | Small Cell Lung... | Prexasertib | 18 Years - | Eli Lilly and Company | |
| A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer | NCT02735980 | Small Cell Lung... | Prexasertib | 18 Years - | Eli Lilly and Company | |
| Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors | NCT03057145 | Solid Tumor | Prexasertib Olaparib | 18 Years - | Dana-Farber Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
